Review

. 2015 Jul;11(7):865-84.

doi: 10.1016/j.jalz.2015.04.005.

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

Michael W Weiner¹, Dallas P Veitch², Paul S Aisen³, Laurel A Beckett⁴, Nigel J Cairns⁵, Jesse Cedarbaum⁶, Michael C Donohue⁷, Robert C Green⁸, Danielle Harvey⁴, Clifford R Jack Jr⁹, William Jagust¹⁰, John C Morris¹¹, Ronald C Petersen¹², Andrew J Saykin¹³, Leslie Shaw¹⁴, Paul M Thompson¹⁵, Arthur W Toga¹⁶, John Q Trojanowski¹⁷; Alzheimer's Disease Neuroimaging Initiative

Affiliations

¹ Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA; Department of Radiology, University of California, San Francisco, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA, USA. Electronic address: michael.weiner@ucsf.edu.
² Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA.
³ Department of Neurosciences, University of California- San Diego, La Jolla, CA, USA.
⁴ Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, Davis, CA, USA.
⁵ Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, MO, USA; Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
⁶ Neurology Early Clinical Development, Biogen Idec, Cambridge, MA, USA.
⁷ Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, San Diego, CA, USA.
⁸ Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
⁹ Department of Radiology, Mayo Clinic, Rochester, MN, USA.
¹⁰ Helen Wills Neuroscience Institute and the School of Public Health, University of California Berkeley, Berkeley, CA, USA.
¹¹ Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
¹² Department of Neurology, Mayo Clinic, Rochester, MN, USA.
¹³ Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
¹⁴ Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
¹⁵ Imaging Genetics Center, Institute for Neuroimaging and Informatics, University of Southern California, Marina Del Rey, CA, USA.
¹⁶ Laboratory of Neuroimaging, Institute of Neuroimaging and Informatics, Keck School of Medicine of University of Southern California Los Angeles, CA, USA.
¹⁷ Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Alzheimer's Disease Core Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Udall Parkinson's Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

PMID: 26194320
PMCID: PMC4659407
DOI: 10.1016/j.jalz.2015.04.005

Review

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

Michael W Weiner et al. Alzheimers Dement. 2015 Jul.

. 2015 Jul;11(7):865-84.

doi: 10.1016/j.jalz.2015.04.005.

Authors

Affiliations

¹ Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA; Department of Radiology, University of California, San Francisco, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA, USA. Electronic address: michael.weiner@ucsf.edu.
² Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA.
³ Department of Neurosciences, University of California- San Diego, La Jolla, CA, USA.
⁴ Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, Davis, CA, USA.
⁵ Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, MO, USA; Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
⁶ Neurology Early Clinical Development, Biogen Idec, Cambridge, MA, USA.
⁷ Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, San Diego, CA, USA.
⁸ Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
⁹ Department of Radiology, Mayo Clinic, Rochester, MN, USA.
¹⁰ Helen Wills Neuroscience Institute and the School of Public Health, University of California Berkeley, Berkeley, CA, USA.
¹¹ Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
¹² Department of Neurology, Mayo Clinic, Rochester, MN, USA.
¹³ Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
¹⁴ Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
¹⁵ Imaging Genetics Center, Institute for Neuroimaging and Informatics, University of Southern California, Marina Del Rey, CA, USA.
¹⁶ Laboratory of Neuroimaging, Institute of Neuroimaging and Informatics, Keck School of Medicine of University of Southern California Los Angeles, CA, USA.
¹⁷ Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Alzheimer's Disease Core Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Udall Parkinson's Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

PMID: 26194320
PMCID: PMC4659407
DOI: 10.1016/j.jalz.2015.04.005

Abstract

Introduction: The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials.

Methods: We searched for ADNI publications using established methods.

Results: ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis.

Discussion: ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.

Keywords: AD biomarker signature; Alzheimer's disease; Amyloid phenotyping; Clinical trial biomarkers; Data-sharing; Tau imaging; Worldwide ADNI.

PubMed Disclaimer

Figures

**Fig. 1**
A model for biomarker dynamics in Alzheimer’s disease (AD) pathogenesis. From Jack et al. [9].

**Fig. 2**
A cerebrospinal fluid (CSF) biomarker signature for Alzheimer’s disease (AD). Signature 1 (red) is AD, signature 2 (green) is the healthy signature. From De Meyer et al. [137].

See this image and copyright information in PMC

References

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–6. - PubMed
1. Khachaturian ZS. Toward a comprehensive theory of Alzheimer’s disease—challenges, caveats, and parameters. Ann N Y Acad Sci. 2000;924:184–93. - PubMed
1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8. - PubMed
1. Petersen RC, Waring SC, Smith GE, Tangalos EG, Thibodeau SN. Predictive value of APOE genotyping in incipient Alzheimer’s disease. Ann N Y Acad Sci. 1996;802:58–69. - PubMed
1. Weiner MW, Aisen PS, Jack CR, Jr, Jagust WJ, Trojanowski JQ, Shaw L, et al. The Alzheimer’s Disease Neuroimaging Initiative: progress report and future plans. Alzheimers Dement. 2010;6:202–2117. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

Affiliations

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

Authors

Affiliations

Abstract

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical